In Vitro Diagnostics Contract Manufacturing Market To Reach $37.45 Billion By 2030

In Vitro Diagnostics Contract Manufacturing Market Growth & Trends

The global in vitro diagnostics contract manufacturing market size is expected to reach USD 37.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.04% over the forecast period.

The market is anticipated to witness lucrative growth potential owing to rising demand for diagnostic devices, an upsurge in point-of-care diagnostics, advancements in molecular testing, and the increasing prevalence of chronic diseases. Moreover, the growing need for cost-effective manufacturing, technological innovation, and stringent regulatory compliance for diagnostics is expected to drive the market revenue stream. Thus, the increasing trend for outsourcing manufacturing services to CMOs and CDMOs to access specialized expertise, streamline production, and accelerate time-to-market among healthcare companies is boosting overall market growth.

The high cost of in-house IVD manufacturing is a significant driver propelling the market growth. The need for high capital investment in infrastructure, specialized equipment, regulatory compliance, and skilled workforce to develop and scale up IVD production will accelerate market growth. These overhead costs strain resources, reducing profitability and flexibility among several small and medium-scale organizations. Thus, by outsourcing manufacturing services to CMOs & CDMOs, companies can lower manufacturing costs and gain access to innovative technologies exclusive of the need for internal capital investment. Moreover, outsourcing allows faster market entry, enhanced scalability, and better resource optimization and offers a competitive edge in the IVD market.

Furthermore, continuous technological advancements are among the major factors accelerating the market demand, specifically for diagnostic devices and testing solutions. Innovations such as molecular diagnostics, next-generation sequencing (NGS), and automation have enhanced the accuracy, speed, and efficiency of IVD manufacturing processes. These advancements assist manufacturers to meet the increasing demand for personalized medicine, point-of-care diagnostics, and faster disease detection methods. Moreover, the integration of AI-driven technologies and data analytics optimizes production workflows and quality assurance processes, enhancing precision and compliance with regulatory standards. Furthermore, numerous healthcare companies are involved in collaboration with contract manufacturers to access such novel technologies to accelerate time-to-market, reduce operational costs, and enhance product scalability. Thus, the integration of advanced technologies by service providers is estimated to drive market growth in the forthcoming years.

 Request a free sample copy or view report summary: In Vitro Diagnostics Contract Manufacturing Market Report

In Vitro Diagnostics Contract Manufacturing Market Report Highlights

• Based on product, the reagents & consumables segment dominated the market with a revenue share of 69.34% in 2023. The segment growth is attributed to increasing demand for rapid diagnostic solutions and personalized medicine. Moreover, increasing preference for molecular diagnostics and point-of-care testing are boosting the need for specialized reagents. In addition, continuous advances in automation and next-generation sequencing (NGS) are further bolstering the demand for high-quality consumables.

• Based on service, the manufacturing services segment held the largest share in 2023. The increasing demand for rapid, high-quality diagnostics and personalized healthcare solutions spurs the demand for scale-up production, thereby expanding the contract services market. In addition, the need for cost-effective production and compliance with stringent regulatory standards drives healthcare companies to outsource manufacturing to meet the growing needs of the IVD market.

• Based on technology, the immunoassay segment accounted for the largest revenue share in 2023. This large revenue share is owing to the rising demand for accurate and rapid diagnostic tests. Moreover, the increasing prevalence of chronic diseases and a growing emphasis on personalized medicine is anticipated to drive segmental growth. In addition, innovations in biomarker discovery and the expansion of point-of-care diagnostics are propelling market expansion.

• Based on end use, the medical device companies segment accounted for the largest revenue share in 2023.Growing demand for advanced, customizable diagnostic solutions and the integration of digital technologies for enhanced accuracy are key factors accelerating segment growth. Moreover, stringent quality standards and the integration of innovative technologies by service providers are major factors accelerating collaboration and partnerships by medical device companies with contract manufacturers that offer innovative capabilities and flexible solutions to meet growing market needs.

• North America dominated the market with a share of 41.91% in 2023. The increasing prevalence of chronic diseases and the demand for advanced diagnostic solutions in the North American region are propelling market expansion. In addition, the rising need for cost-effective manufacturing solutions is leading healthcare companies to outsource IVD production. Regulatory support and innovation in diagnostic technologies further drive market momentum, creating opportunities for growth and collaboration within the contract manufacturing sector.

In Vitro Diagnostics Contract Manufacturing Market Segmentation

Grand View Research has segmented the In Vitro Diagnostics (IVD) contract manufacturing market based on product, service, technology, end use, and region:

In Vitro Diagnostics Contract Manufacturing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Reagents & Consumables

• Software & Services

In Vitro Diagnostics Contract Manufacturing Service Outlook (Revenue, USD Million, 2018 - 2030)

• Manufacturing Services

• Assay Development Services

• Other Services

In Vitro Diagnostics Contract Manufacturing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassays

• Clinical Chemistry

• Molecular Diagnostics

• Hematology

• Microbiology

• Coagulation

• Others

In Vitro Diagnostics Contract Manufacturing End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Medical Device Companies

• Academic & Research Institutions

• Others

In Vitro Diagnostics Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Mexico

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• China

• Japan

• India

• Australia

• South Korea

• Thailand

• Latin America

• Brazil

• Argentina

• Middle East and Africa (MEA)

• South Africa

• Saudi Arabia

• UAE

• Kuwait

List of Key Players in the In Vitro Diagnostics Contract Manufacturing Market

• Jabil Inc.

• Sanmina Corporation

• TE Connectivity

• Celestica Inc.

• Savyon Diagnostics

• West Pharmaceutical Services, Inc.

• Thermo Fisher Scientific

• KMC Systems

• Cenogenics Corporation

• Novo Biomedical

• Cone Bioproducts

• Invetech

• AVIOQ Inc.

• Meridian Bioscience Inc.

• Nemera